{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T22:48:20Z","timestamp":1767912500288,"version":"3.49.0"},"reference-count":39,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"7","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2012,10]]},"DOI":"10.1097\/mph.0b013e3182667bc7","type":"journal-article","created":{"date-parts":[[2013,6,13]],"date-time":"2013-06-13T21:30:11Z","timestamp":1371159011000},"page":"e282-e288","source":"Crossref","is-referenced-by-count":8,"title":["Characteristics and Prognosis of B-cell Lymphoma in HIV-infected Children in the HAART Era"],"prefix":"10.1097","volume":"34","author":[{"given":"C\u00e9cile","family":"Godot","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Catherine","family":"Patte","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"St\u00e9phane","family":"Blanche","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pierre","family":"Rohrlich","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Catherine","family":"Dollfus","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marie-Dominique","family":"Tabone","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-29-20210227","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1097\/01.inf.0000154324.59426.8d","article-title":"Malignancy in perinatally human immunodeficiency virus-infected children in the United States.","volume":"24","author":"Kest","year":"2005","journal-title":"Pediatr Infect Dis J"},{"key":"R2-29-20210227","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1097\/INF.0b013e31821ba148","article-title":"Epidemiologic trends of cancer diagnoses among HIV-infected children in Spain from 1997 to 2008.","volume":"30","author":"Alvaro-Meca","year":"2011","journal-title":"Pediatr Infect Dis J"},{"key":"R3-29-20210227","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1001\/jama.284.2.205","article-title":"Risk of cancer in children with AIDS. AIDS-Cancer Match Registry Study Group.","volume":"284","author":"Biggar","year":"2000","journal-title":"JAMA"},{"key":"R4-29-20210227","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1200\/JCO.2006.06.6506","article-title":"Cancer rates after year 2000 significantly decrease in children with perinatal HIV infection: a study by the Italian register for HIV infection in children.","volume":"25","author":"Chiappini","year":"2007","journal-title":"J Clin Oncol"},{"key":"R5-29-20210227","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1136\/adc.76.4.330","article-title":"Malignancies in UK children with HIV infection acquired from mother to child transmission.","volume":"76","author":"Evans","year":"1997","journal-title":"Arch Dis Child"},{"key":"R6-29-20210227","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1200\/JCO.1998.16.5.1729","article-title":"Cancer in human immunodeficiency virus-infected children: a case series from the Childrens Cancer Group and the National Cancer Institute.","volume":"16","author":"Granovsky","year":"1998","journal-title":"J Clin Oncol"},{"key":"R7-29-20210227","doi-asserted-by":"crossref","first-page":"3854","DOI":"10.1200\/JCO.2000.18.22.3854","article-title":"Human immunodeficiency virus-related cancer in children: incidence and treatment outcomereport of the Italian Register.","volume":"18","author":"Caselli","year":"2000","journal-title":"J Clin Oncol"},{"key":"R8-29-20210227","first-page":"778","article-title":"Treatment options for HIV-positive children with B-Cell lymphoma.","volume":"55","author":"Davidson","year":"2010","journal-title":"Pediatr Blood Cancer"},{"key":"R9-29-20210227","first-page":"1","article-title":"Revised surveillance case definitions for HIV infection among adults, adolescents, and children aged 18 months and for HIV infection and AIDS among children aged 18 months to 13 years-United States.","volume":"57","author":"Schneider","year":"2008","journal-title":"MMWR Recomm Rep"},{"key":"R10-29-20210227","first-page":"332","article-title":"Classification, staging and end results of treatment of childhood non-Hodgkins lymphomas: dissimilarities from lymphomas in adults.","volume":"7","author":"Murphy","year":"1998","journal-title":"Semin Oncol"},{"key":"R12-29-20210227","doi-asserted-by":"crossref","first-page":"547","DOI":"10.3109\/00313025.2010.508786","article-title":"Primary central nervous system lymphoma: a clinicopathological study of 75 cases.","volume":"42","author":"Preusser","year":"2010","journal-title":"Pathology"},{"key":"R13-29-20210227","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1007\/s00247-009-1170-4","article-title":"Central nervous system manifestations of HIV infection in children.","volume":"39","author":"George","year":"2009","journal-title":"Pediatr Radiol"},{"key":"R14-29-20210227","doi-asserted-by":"crossref","first-page":"3370","DOI":"10.1182\/blood.V97.11.3370","article-title":"The Societe Francaise dOncologie Pediatrique LMB89 protocol: highly effective multiagent chemotherapy tailored to the tumor burden and initial response in 561 unselected children with B-cell lymphomas and L3 leukemia.","volume":"97","author":"Patte","year":"2001","journal-title":"Blood"},{"key":"R15-29-20210227","doi-asserted-by":"crossref","first-page":"2773","DOI":"10.1182\/blood-2006-07-036673","article-title":"Results of the randomized international FABLMB96 trial for intermediate risk B-cell non-Hodgkin lymphoma in children and adolescents: it is possible to reduce treatment for the early responding patients.","volume":"109","author":"Patte","year":"2007","journal-title":"Blood"},{"key":"R17-29-20210227","first-page":"316","article-title":"Estimation of the number of new HIV diagnoses in children in France from 2003 to 2006.","volume":"30","author":"Lot","year":"2010","journal-title":"BEH"},{"key":"R18-29-20210227","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1093\/jnci\/91.12.1051","article-title":"Cancer surveillance series: recent trends in childhood cancer incidence and mortality in the United States.","volume":"91","author":"Linet","year":"1999","journal-title":"J Natl Cancer Inst"},{"key":"R19-29-20210227","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1097\/CEJ.0b013e32833876c0","article-title":"Incidence of childhood cancer in France: National Children Cancer Registries, 2000-2004.","volume":"19","author":"Lacour","year":"2010","journal-title":"Eur J Cancer Prev"},{"key":"R20-29-20210227","doi-asserted-by":"crossref","first-page":"2393","DOI":"10.1001\/jama.289.18.2393","article-title":"Risk factors for pediatric human immunodeficiency virus-related malignancy.","volume":"289","author":"Pollock","year":"2003","journal-title":"JAMA"},{"key":"R21-29-20210227","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1016\/S0929-693X(00)80154-2","article-title":"Lymphomas in children infected with HIV-1.","volume":"7","author":"Gandemer","year":"2000","journal-title":"Arch Pediatr"},{"key":"R22-29-20210227","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1016\/S1470-2045(09)70282-7","article-title":"Effect of immunodeficiency, HIV viral load, and antiretroviral therapy on the risk of individual malignancies (FHDH-ANRS CO4): a prospective cohort study.","volume":"10","author":"Guiguet","year":"2009","journal-title":"Lancet Oncol"},{"key":"R24-29-20210227","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1002\/ijc.2910290406","article-title":"Final case reporting from the Ugandan prospective study of the relationship between EBV and Burkitts lymphoma.","volume":"29","author":"Geser","year":"1982","journal-title":"Int J Cancer"},{"key":"R25-29-20210227","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1002\/1097-0215(20010601)92:5<622::AID-IJC1256>3.0.CO;2-K","article-title":"A case-control study of human immunodeficiency virus infection and cancer in adults and children residing in Kampala, Uganda.","volume":"92","author":"Newton","year":"2001","journal-title":"Int J Cancer"},{"key":"R26-29-20210227","doi-asserted-by":"crossref","first-page":"2171","DOI":"10.1200\/JCO.2001.19.8.2171","article-title":"Chemotherapy for human immunodeficiency virus-associated non-Hodgkins lymphoma in combination with highly active antiretroviral therapy.","volume":"19","author":"Ratner","year":"2001","journal-title":"J Clin Oncol"},{"key":"R27-29-20210227","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1046\/j.1365-2141.2001.02656.x","article-title":"Influence of highly active anti-retroviral therapy on response to treatment and survival in patients with acquired immunodeficiency syndrome-related non-Hodgkins lymphoma treated with cyclophosphamide, hydroxydoxorubicin, vincristine and prednisone.","volume":"112","author":"Navarro","year":"2001","journal-title":"Br J Haematol"},{"key":"R28-29-20210227","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.1097\/QAD.0b013e32833a0961","article-title":"Survival of non-Hodgkin lymphoma patients with and without HIV infection in the era of combined antiretroviral therapy.","volume":"24","author":"Chao","year":"2010","journal-title":"AIDS"},{"key":"R29-29-20210227","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/S1474-4422(09)70091-2","article-title":"Therapeutic challenges in primary CNS lymphoma.","volume":"8","author":"Morris","year":"2009","journal-title":"Lancet Neurol"},{"key":"R30-29-20210227","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/S1658-3876(10)50023-2","article-title":"Improved survival with combined chemo-radiotherapy in primary central nervous system lymphoma.","volume":"3","author":"Abdelsalam","year":"2009","journal-title":"Hematol Oncol Stem Cell Ther"},{"key":"R31-29-20210227","doi-asserted-by":"crossref","first-page":"1725","DOI":"10.1097\/00002030-199714000-00009","article-title":"Intravenous methotrexate for primary central nervous system non-Hodgkins lymphoma in AIDS.","volume":"11","author":"Jacomet","year":"1997","journal-title":"AIDS"},{"key":"R32-29-20210227","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1002\/pbc.22752","article-title":"Treatment of primary CNS lymphoma with high-dose methotrexate in immunocompetent pediatric patients.","volume":"55","author":"Shah","year":"2010","journal-title":"Pediatr Blood Cancer"},{"key":"R33-29-20210227","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1007\/s11060-010-0252-3","article-title":"Primary CNS lymphoma in HIV positive and negative patients: comparison of clinical characteristics, outcome and prognostic factors.","volume":"101","author":"Bayraktar","year":"2011","journal-title":"J Neurooncol"},{"key":"R34-29-20210227","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/S1470-2045(06)70664-7","article-title":"CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group.","volume":"7","author":"Pfreundschuh","year":"2006","journal-title":"Lancet Oncology"},{"key":"R35-29-20210227","doi-asserted-by":"crossref","first-page":"1538","DOI":"10.1182\/blood-2005-04-1437","article-title":"Rituximab does not improve clinical outcome in a randomized phase 3 trial of CHOP with or without rituximab in patients with HIV-associated non-Hodgkin lymphoma: AIDS-Malignancies Consortium Trial 010.","volume":"106","author":"Kaplan","year":"2005","journal-title":"Blood"},{"key":"R36-29-20210227","doi-asserted-by":"crossref","first-page":"4123","DOI":"10.1200\/JCO.2005.05.4684","article-title":"Phase II trial of CHOP plus rituximab in patients with HIV-associated non-Hodgkins lymphoma.","volume":"24","author":"Boue","year":"2006","journal-title":"J Clin Oncol"},{"key":"R37-29-20210227","doi-asserted-by":"crossref","first-page":"3008","DOI":"10.1182\/blood-2009-08-231613","article-title":"Rituximab plus concurrent infusional EPOCH chemotherapy is highly effective in HIV-associated B-cell non-Hodgkin lymphoma.","volume":"115","author":"Sparano","year":"2010","journal-title":"Blood"},{"key":"R38-29-20210227","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1097\/01.cco.0000239881.16216.05","article-title":"Advances in the management of HIV-related non-Hodgkin lymphoma.","volume":"18","author":"Behler","year":"2006","journal-title":"Curr Opin Oncol"},{"key":"R39-29-20210227","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1093\/jac\/dki050","article-title":"Pharmacokinetic interaction between chemotherapy for non-Hodgkins lymphoma and protease inhibitors in HIV-1-infected patients.","volume":"55","author":"Cruciani","year":"2005","journal-title":"J Antimicrob Chemother"},{"key":"R40-29-20210227","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1002\/1097-0142(20010101)91:1<155::AID-CNCR20>3.0.CO;2-B","article-title":"Concomitant cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy plus highly active antiretroviral therapy in patients with human immunodeficiency virus-related, non-Hodgkin lymphoma.","volume":"91","author":"Vaccher","year":"2001","journal-title":"Cancer"},{"key":"R41-29-20210227","doi-asserted-by":"crossref","first-page":"2943","DOI":"10.1182\/blood-2004-05-1747","article-title":"Protease inhibitors potentiate chemotherapy-induced neutropenia.","volume":"104","author":"Bower","year":"2004","journal-title":"Blood"},{"key":"R42-29-20210227","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.critrevonc.2008.10.013","article-title":"Drug interactions between antineoplastic and antiretroviral therapies: Implications and management for clinical practice.","volume":"72","author":"Mounier","year":"2009","journal-title":"Crit Rev Oncol Hematol"}],"container-title":["Journal of Pediatric Hematology\/Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MPH.0b013e3182667bc7","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,14]],"date-time":"2021-05-14T04:13:04Z","timestamp":1620965584000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00043426-201210000-00029"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,10]]},"references-count":39,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2012]]}},"URL":"https:\/\/doi.org\/10.1097\/mph.0b013e3182667bc7","relation":{},"ISSN":["1077-4114"],"issn-type":[{"value":"1077-4114","type":"print"}],"subject":[],"published":{"date-parts":[[2012,10]]}}}